Clinical Trial: NCT06284564
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | M.D. Anderson Cancer Center |
| Information Provided By: | M.D. Anderson Cancer Center |
| Last Update Posted: | 2026-10-15 |
Study Overview
Brief Summary
To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.
Official Title
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
Conditions
Metastatic Renal Cell Carcinoma
Intervention / Treatment
- Drug: Evolocumab
- Drug: Nivolumab
Other Study ID Numbers
- 2023-0538
- NCI-2024-03604
Start Date (Actual)
2024-08-07
Primary Completion Date (Estimated)
2028-10-01
Study Completion Date (Estimated)
2028-10-01
Enrollment (Actual)
10
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | M.D. Anderson Cancer Center |
| Information Provided By: | M.D. Anderson Cancer Center |
| Last Update Posted: | 2026-10-15 |
Study Overview
Brief Summary
To learn if evolocumab and nivolumab can control metastatic and refractory renal cell carcinoma. The safety of this drug combination will also be studied.
Official Title
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
Conditions
Metastatic Renal Cell Carcinoma
Intervention / Treatment
- Drug: Evolocumab
- Drug: Nivolumab
Other Study ID Numbers
- 2023-0538
- NCI-2024-03604
Start Date (Actual)
2024-08-07
Primary Completion Date (Estimated)
2028-10-01
Study Completion Date (Estimated)
2028-10-01
Enrollment (Actual)
10
Study Type
Interventional
Phase
Phase 2